Mr. Renaud joined Bain Capital Life Sciences in 2022. From 2014 to 2021, he was Chief Executive Officer of Translate Bio (Nasdaq: TBIO) which was acquired by Sanofi in 2021. Prior to that he was President and Chief Executive Officer of Idenix Pharmaceuticals (Nasdaq: IDIX) which was acquired by Merck in 2014. Prior to his career in the biotech industry, Ron was a biotechnology research analyst at JP Morgan and Bear Stearns. Earlier in his career, Ron held various roles at Amgen (Nasdaq: AMGN) as well as at the Dana-Farber Cancer Institute.
Mr. Renaud received an MBA from the University of Southern California Marshall School of Business and a BA from Saint Anselm College.